Rabbit Recombinant Monoclonal SLFN12 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
Application | Reactivity | Dilution info | Notes |
---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Ribonuclease which is part of an E2/17beta-estradiol-induced pro-apoptotic signaling pathway. E2 stabilizes the PDE3A/SLFN12 complex in the cytosol, promoting the dephosphorylation of SLFN12 and activating its pro-apoptotic ribosomal RNA/rRNA ribonuclease activity. This apoptotic pathway might be relevant in tissues with high concentration of E2 and be for instance involved in placenta remodeling (PubMed:31420216, PubMed:34272366, PubMed:34707099, PubMed:35104454). May play a role in cell differentiation (PubMed:30045019).
Ribonuclease SLFN12, Schlafen family member 12, SLFN12
Rabbit Recombinant Monoclonal SLFN12 antibody - conjugated to PE.
IgG
Rabbit
PE
Ex: 480;565nm, Em: 578nm
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Liquid
Monoclonal
EPR20904-32
Affinity purification Protein A
Blue Ice
1-2 weeks
+4°C
+4°C
Upon delivery aliquot
Avoid freeze / thaw cycle, Store in the dark
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
This supplementary information is collated from multiple sources and compiled automatically.
SLFN12 also known as Schlafen family member 12 is a protein that plays a role in protein synthesis regulation and innate immunity. It carries a mass of approximately 65 kDa. The protein shows expression in multiple human tissues including the colon small intestine and prostate. SLFN12 contains a notable AAA+ ATPase domain which suggests involvement in processes requiring energy such as molecular chaperone activity. Researchers have studied its expression pattern noting its presence at the cellular level which hints at diverse functional implications across various cells.
SLFN12 modulates the differentiation of cells and appears to play a role in immune response. It does not form part of a large protein complex. It functions independently to exert effects specifically influencing maturation of specific immune cells and contributing to maintaining cellular homeostasis. Its role in differentiation makes it significant in balancing immune responses ensuring cells reach necessary maturity to perform their function in defense mechanisms.
Studies highlight that SLFN12 contributes to the regulation of protein synthesis and the immune response pathway. In the synthesis pathway it potentially interacts with ribosomal proteins to regulate production of proteins modulating cell homoeostasis and growth. Meanwhile its involvement in the immune response pathway shows interaction with other SLFN family proteins altering cellular responses to microbial infections. Research also suggests it operates alongside proteins like SLFN11 to ensure effective cellular defense against pathogenic attacks.
Researchers have associated SLFN12 with inflammatory bowel disease and certain types of cancer such as prostate cancer. Its expression patterns in inflamed tissue suggest that SLFN12 may mediate inflammatory responses exacerbating or alleviating the condition. In prostate cancer SLFN12 seems to interact with the androgen receptor pathway potentially influencing cancer cell proliferation. Understanding these interactions and their pathological consequences will provide insights into its role in disease mechanisms and offer perspectives for therapeutics targeting SLFN12-mediated pathways.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com